Jing-Jing Tong1, Sheng-Qian Xu2, He-Xiang Zong1, Mei-Juan Pan1, Yu-Zhu Teng1, Jian-Hua Xu1. 1. Department of Rheumatology & Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. 2. Department of Rheumatology & Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. xsqian-1112@163.com.
Abstract
OBJECTIVES: To explore the prevalence and risk factors of osteoporosis (OP) and vertebral osteoporotic fracture (VOPF) in patients with rheumatoid arthritis (RA). METHODS: Anteroposterior and lateral X-ray examination of the vertebral column (T4-L4) was used for the semi-quantitative assessment of VOPF. Bone mineral density was measured by dual-energy X-ray absorptiometry. RESULTS: Of 865 RA patients, the prevalence of OP and VOPF was 33.6% and 20.2%, respectively. Patients with OP or VOPF were older, and had longer term use and a larger daily amount and cumulative dose of glucocorticoids (GCs), longer disease duration, and higher Health Assessment Questionnaire (HAQ) scores and Sharp scores than patients without OP or VOPF (P < 0.05). OP was also correlated with higher disease activity. The patients treated with GCs had higher incidences of OP and VOPF than the patients without GCs (P < 0.05). The cutoff values in the area under curve (AUC) of the daily dose or treatment course of GCs-VOPF were 9 mg and 37.5 days. Older age, female sex, and a higher Sharp score were risk factors for OP in RA patients, while higher BMI was a protective factor. Older age and a high GC daily dose were risk factors for VOPF in RA patients. CONCLUSIONS: RA patients have a high prevalence of OP and VOPF. Older age, female sex, lower BMI, and higher activity and severity of RA are closely related with OP. Older age and a higher GC daily dose are risk factors for VOPF in RA patients. Key Points • Older age, female sex, lower BMI, and a higher Sharp score were risk factors for OP in RA patients. • Older age and a high GC daily dose were risk factors for VOPF in RA patients. • OP and VOPF in RA patients were correlated with longer disease duration and higher severity of RA.
OBJECTIVES: To explore the prevalence and risk factors of osteoporosis (OP) and vertebral osteoporotic fracture (VOPF) in patients with rheumatoid arthritis (RA). METHODS: Anteroposterior and lateral X-ray examination of the vertebral column (T4-L4) was used for the semi-quantitative assessment of VOPF. Bone mineral density was measured by dual-energy X-ray absorptiometry. RESULTS: Of 865 RA patients, the prevalence of OP and VOPF was 33.6% and 20.2%, respectively. Patients with OP or VOPF were older, and had longer term use and a larger daily amount and cumulative dose of glucocorticoids (GCs), longer disease duration, and higher Health Assessment Questionnaire (HAQ) scores and Sharp scores than patients without OP or VOPF (P < 0.05). OP was also correlated with higher disease activity. The patients treated with GCs had higher incidences of OP and VOPF than the patients without GCs (P < 0.05). The cutoff values in the area under curve (AUC) of the daily dose or treatment course of GCs-VOPF were 9 mg and 37.5 days. Older age, female sex, and a higher Sharp score were risk factors for OP in RA patients, while higher BMI was a protective factor. Older age and a high GC daily dose were risk factors for VOPF in RA patients. CONCLUSIONS: RA patients have a high prevalence of OP and VOPF. Older age, female sex, lower BMI, and higher activity and severity of RA are closely related with OP. Older age and a higher GC daily dose are risk factors for VOPF in RA patients. Key Points • Older age, female sex, lower BMI, and a higher Sharp score were risk factors for OP in RA patients. • Older age and a high GC daily dose were risk factors for VOPF in RA patients. • OP and VOPF in RA patients were correlated with longer disease duration and higher severity of RA.
Authors: N Guañabens; J M Olmos; J L Hernández; D Cerdà; C Hidalgo Calleja; J A Martinez López; L Arboleya; F J Aguilar Del Rey; S Martinez Pardo; I Ros Vilamajó; X Suris Armangué; D Grados; C Beltrán Audera; E Suero-Rosario; I Gómez Gracia; A Salmoral Chamizo; I Martín-Esteve; H Florez; A Naranjo; S Castañeda; S Ojeda Bruno; S García Carazo; A García Vadillo; L López Vives; À Martínez-Ferrer; H Borrell Paños; P Aguado Acín; R Castellanos-Moreira; C Tebé; C Gómez-Vaquero Journal: Osteoporos Int Date: 2021-01-18 Impact factor: 4.507
Authors: Bernardo D'Onofrio; Michele di Lernia; Ludovico De Stefano; Serena Bugatti; Carlomaurizio Montecucco; Laura Bogliolo Journal: J Clin Med Date: 2022-04-22 Impact factor: 4.964